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A third serotype of human parechovirus (HPeV) has
been recently isolated from stool specimens of a young
Japanese child with transient paralysis. We report 3 addi-
tional cases of neonatal sepsis caused by HPeV-3 in the fall
of 2001 in Canadian infants 7–27 days old. All children
were hospitalized with high fever, erythematous rash, and
tachypnea for a median of 5 days. The viruses isolated
from nasopharyngeal aspirates grew slowly on tertiary
monkey kidney cells and were successfully passaged on
Vero cells. The predicted amino acid identity of the VP0-
VP3-VP1 region of the three viruses was 74.6%–74.8%,
73.4%–73.6%, and 97.0%–97.1% when compared to
HPeV-1, -2, and –3 prototype strains, respectively.
Although different, our isolates were closely related; amino
acid identity was 99.6%–100% for the last 3 proteins.
V
iruses belonging to the Picornaviridae family have
been recently reclassified into 9 genera based on acid
lability, serum neutralization, and sequence homologies
(1). The Parechovirus genus is 1 of 5 picornavirus genera,
along with enteroviruses, hepatoviruses, rhinoviruses, and
kobuviruses, known to infect humans. Human pare-
choviruses (HPeV) 1 and 2, previously known as
echoviruses 22 and 23, were first isolated in 1956 (2).
These viruses, in particular, HPeV-1, have been associated
with gastrointestinal and respiratory tract infections, as
well as occasional cases of encephalitis and flaccid paral-
ysis (3–7). A new serotype of HPeV (HPeV-3) was
described in 2004; the strain was isolated from a stool
specimen of a 1-year-old Japanese girl with transient paral-
ysis (8). Preliminary HPeV-3 seroepidemiologic studies
from Japan indicated a seroprevalence of 85% in children
entering elementary school (8). However, clinical informa-
tion related to this viral infection is limited, and the virus
has not been reported outside Japan. We report 3 cases of
neonatal infection caused by HPeV-3 in Canada.
Case Reports
Case 1
A 27-day-old boy, born at term, was hospitalized on
September 5, 2001, for fever of unknown origin. The fever
appeared the day before without respiratory or gastroin-
testinal symptoms. His father had had sinusitis, and his 2-
year-old brother had had an upper respiratory tract
infection in the preceding few days. 
On initial examination, the baby was alert, with a tem-
perature of 39.4°C, a respiratory rate of 40 breaths per
minute, heart rate of 143 beats per minute, and oxygen
(O2) saturation at 98% (in room air). Blood pressure was
not recorded. Results of physical examination were other-
wise normal, with no lung rales, normal tympanic mem-
branes, and no rash. Leukocyte count was 4.5 x 109 cells/L
(30% neutrophils, 0% band forms, 60% lymphocytes),
hemoglobin level was 123 g/L, and platelet count was 166
x 109 cells/L. C-reactive protein was undetectable.
Urinalysis results were normal. A lumbar puncture was
performed, and analysis of the cerebrospinal fluid showed
erythrocytes with no leukocytes, a glucose level of 2.8
mmol/L (normal 2.2–4.4 mmol/L), and a protein level of
0.44 g/L (normal 0.15–0.45 g/L). Chest radiograph results
were normal. The patient was admitted with a diagnosis of
probable viremia, and intravenous antimicrobial drugs
(ampicillin and gentamicin) were administered until the
results of blood cultures were available.
The following day, the infant experienced an episode of
O2 desaturation (90%) with increased respiratory rate
(70/min) and temperature (39.7°C). A maculopapular rash
was also noted on the trunk and extremities. Chest radi-
ograph results remained normal. Because of the infant’s
tachypnea, a nasopharyngeal aspirate (NPA) was obtained
for human respiratory syncytial virus (RSV) antigen test-
ing (Test Pack, Abbott Laboratories, Abbott Park, IL) and
direct immunofluorescence assays (Bartels, Carlsbad, CA)
for adenoviruses and parainfluenza viruses 1–3. Results of
all rapid antigenic tests were negative. NPA was inoculat-
ed into numerous cell lines, including Madin Darby kid-
ney, LLC-MK2 (tertiary monkey kidney), Hep-2, human
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Québec City, Québec, Canadaforeskin fibroblast, Vero, Mink lung, human lung adeno-
carcinoma (A-549), human rhabdomyosarcoma, trans-
formed human kidney (293), and human colon
adenocarcinoma (HT-29) cells. The patient’s condition
gradually improved over the next 3 days, fever disap-
peared, and O2 saturation returned to normal. Four days
after admission, the patient was afebrile and eupneic. A
pale macular rash was still present on the trunk. The leuko-
cyte count was 12.5 x 109 cells/L (8% neutrophils, 1%
band forms, and 75% lymphocytes), with hemoglobin at
138 g/L and a low platelet count of 101 x 109 cells/L.
Blood and cerebrospinal fluid cultures remained negative,
and the urine culture was interpreted as bacterial contami-
nation. The patient was discharged after 5 days of hospi-
talization with a presumptive diagnosis of viremia and
mild reactive thrombocytopenia. Intravenous antimicro-
bial drugs were switched to oral amoxicillin for 5 more
days. The viral culture of NPA was positive for a non-
hemadsorbing virus (CAN01-81235) that initially grew on
LLC-MK2 cells after 18 days of incubation. 
Case 2
A 20-day-old girl, born at term, was hospitalized on
September 27, 2001, for high fever and irritability. She
was seen 2 days earlier with an acute upper respiratory
tract infection with rhinorrhea and conjunctivitis, for
which she was receiving topical erythromycin. The day
before her hospitalization, her mother also noted a diffuse
macular eruption. The patient had been in contact with her
3-year-old brother who had an upper respiratory tract
infection a few days before. 
On initial physical examination, the patient was con-
scious but irritable. Her temperature was 39.0°C, blood
pressure was normal for age, respiratory rate was 48
breaths per minute, and heart rate was 190 beats per
minute. No O2 desaturation and no rales at lung ausculta-
tion were noted. A pale erythematous rash was present on
the trunk and the limbs. Otitis media was not observed. At
admission, she had a leukocyte count of 5.6 x 109 cells/L
with 36% neutrophils, 10% band forms, and 33% lympho-
cytes. Hemoglobin level was 104 g/L, and platelet count
was 296 x 109 cells/L. The C-reactive protein level was
normal at 4 mg/L. Urinalysis results were normal, and
examination of the cerebrospinal fluid showed 2 x 106
leukocytes/L, a glucose level of 3.2 mmol/L, and a protein
level of 0.53 g/L. Chest radiograph results were normal,
and the child was hospitalized with a diagnosis of viremia
or bacteremia. Intravenous ampicillin and gentamicin were
administered after blood and urine samples were obtained
for cultures. 
The next day, the patient had an episode of O2 desatu-
ration (89% in room air), which led to her transfer to the
intensive care unit for O2 administration and monitoring.
Her temperature was 39.4°C, with a respiratory rate of 60
breaths per minute and a heart rate of 210 beats per minute.
The rash had disappeared by that time. Results of chest
radiograph remained normal. NPA was obtained for rapid
antigenic tests and viral culture. Antigenic test results were
negative. The infant responded well to O2 supplementation
and was discharged from the intensive care unit after 24
hours. Fever disappeared 3 days after admission, and res-
piratory rate and O2 saturation gradually normalized. On
day 3, the leukocyte count was 13.5 x 109 cells/L, with
13% neutrophils, 1% band forms, and 79% lymphocytes.
The hemoglobin level was 102 g/L, with a platelet count of
180 x 109 cells/L. Antimicrobial drugs were discontinued
after 4 days, since blood, urine, and cerebrospinal fluid
cultures remained negative. The infant was discharged on
day 5 of hospitalization with a diagnosis of viral infection
of the upper respiratory tract accompanied by conjunctivi-
tis. Viral culture of the stools collected the day after admis-
sion was negative. Viral culture of the NPA specimen was
positive for a nonhemadsorbing virus (CAN01-81554)
after 14 days of incubation on LLC-MK2 cells.
Case 3
A 7-day-old girl, who was born at term without com-
plications, was brought to the hospital on December 16,
2001, for a recent onset of fever, irritability, and loss of
appetite. Medical history showed that her mother had an
upper respiratory tract infection 3 days before with cough,
fever, sore throat, and a faint rash on her arms. She had
been treated with clarithromycin for sinusitis during the
last month of her pregnancy. The patient had a 2.5-year-old
brother who was in good health.
On initial medical evaluation, the infant was irritable
and refused breastfeeding but was conscious. She had no
history of respiratory or gastrointestinal infections. Her
rectal temperature was 39.2°C, with a heart rate of 150
beats per minute, blood pressure of 82/39 mm Hg, and a
respiratory rate of 62 breaths per minute. No bulging of the
fontanel was observed, and the lungs were clear on aus-
cultation. An erythematous rash involved the trunk and
axillary area without petechiae. Initial laboratory tests
showed a leukocyte count of 8.0 x 109 cells/L, with 71%
neutrophils, 5% band forms, and 18% lymphocytes.
Hemoglobin level was 162 g/L, and platelet count was 199
x 109 cells/L. C-reactive protein level was normal at 11
mg/L. Urinalysis results were normal, and cerebrospinal
fluid contained 147 (144 erythrocytes and 3 leukocytes) x
106 cells/L, with a glucose level of 3.1 mmol/Land protein
level of 0.74 g/L. A chest radiograph did not show lung
infiltrates. The child was hospitalized with an initial diag-
nosis of bacteremia, and treatment with intravenous ampi-
cillin and gentamicin was instituted after blood and urine
samples were collected for culture. 
RESEARCH
104 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 1, January 2005The next day, the erythrodermialike rash became more
diffuse and confluent. Rectal temperature was at 38.5 C,
and the infant was tachypneic but with good O2 saturation
(97%) in room air. Aphysical examination showed bilater-
al acute otitis media, which was confirmed by an ear-nose-
throat specialist. The peripheral leukocyte count increased
to 11.8 x 109 cells/L, with 69% neutrophils and 20% lym-
phocytes, whereas the platelet count had dropped to 145 x
109 cells/L. Liver transaminases were normal, and the
chest radiograph showed no infiltrates. Because of the
infant’s tachypnea, an NPA was obtained. All rapid anti-
genic test results were negative, and the NPA was cultured
for virus. At this point, the regimen was changed to cefo-
taxime and gentamicin.
Over the next 4 days, the patient’s condition progres-
sively improved: fever decreased, breastfeeding improved,
and respiratory rate normalized. In addition, the rash grad-
ually faded, and areas of desquamation were noted. On her
last day of hospitalization (5 days after admission), the
infant was afebrile and eupneic. The leukocyte count was
13.5 x 109 cells/L, with 20% neutrophils and 66% lym-
phocytes, and the platelet count had dropped to 127 x 109
cells/L. Results of a streptozyme test were negative. All
bacterial cultures of specimens collected at the time of
admission (urine, blood, and cerebrospinal fluid) were
negative. The patient was discharged from the hospital
with diagnoses of bilateral acute otitis media, cutaneous
eruption related to a viral infection, and reactive thrombo-
cytopenia. On follow-up, 2 days after discharge, the infant
was in good health. Viral cultures of urine and stools col-
lected during the hospitalization were negative. However,
viral culture from the NPA specimen was positive for a
nonhemadsorbing virus (CAN01-82853) growing in LLC-
MK2 cells after 16 days of incubation.
Laboratory Findings
All 3 viruses initially grew in LLC-MK2 cells after
14–18 days. On passage, however, the viruses grew rapid-
ly (in ≈4–5 days) in Vero cells, with cytopathic effects sim-
ilar to those of enteroviruses. The viruses could not be
neutralized by pools of antisera against human
enteroviruses or by specific antisera for HPeV-1 and -2
(formerly echovirus-22 and -23). Immunofluorescence
assays using antibodies against common respiratory
pathogens (influenza A and B, parainfluenza viruses 1–3,
RSV, adenovirus) and reverse transcription–polymerase
chain reaction (RT-PCR) assays for human metapneu-
movirus (9) were all negative. 
More than 2 years after these patients were treated, and
after the initial description of HPeV-3 (8), 2 RT-PCR
assays for HPeV-3 were performed with infected Vero cell
culture supernatants and were positive. The first set of
primers amplified an 810-bp fragment between the 5′
untranslated region (5′ UTR) and the VP0 gene, whereas
the second set amplified a 2,030-bp fragment between the
VP0 and 2A genes of HPeVs as reported (8). Amplified
products were sequenced with an automated DNA
sequencer (ABI 377A; Perkin-Elmer Applied Biosystems,
Foster City, CA), and the nucleotide and deduced amino
acid sequences were aligned along with representative
strains from other HPeVs by using ClustalW. 
When compared to prototype strains representative of
HPeV-1 (GenBank accession no. S45208), HPeV-2 (no.
AF055846), and HPeV-3 (no. AB084913), the nucleotide
identity of the 3 Canadian strains for part of the 5′ UTR
region was 88.0%–88.9% (HPeV-1), 80.6%–82.9% (HPeV-
2), and 93.5%–94.3% (HPeV-3) (Figure 1). Nucleotide
identity was 97.2%–98.1% between the 3 Canadian isolates
for the same region. The nucleotide identity of the
Canadian strains for the VP0-VP3-VP1 region (2,313
nucleotides, 771 amino acids) was 70.9%–71% (HPeV-1),
69.5%–69.5% (HPeV-2), and 96.0%–96.2% (HPeV-3).
Similarly, the predicted amino acid identity for this region
was 74.6%–74.8%, 73.4%–73.6%, and 97.0%–97.1%
when compared to HPeV-1, -2 and -3 prototype strains,
respectively (online Appendix Figure, available from
http://www.cdc.gov/ncidod/EID/vol11no01/04/0606_app.
htm). The Canadian strains were closely related, with
nucleotide and amino acid identities of 99.2%–100% and
99.6%–100%, respectively, for these 3 capsid proteins.
Contrasting with HPeV-1 and -2 strains, but similar to the
HPeV-3 prototype, the RGD motif located near the
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Figure 1. Comparison of the partial nucleotide
sequences of human parechovirus (HPeV)-3
Canadian isolates no. 81235, 81554, and
82853 with reference sequences of HPeV-1,
-2 and -3 (GenBank accession no. S45208,
AF055846, and AB084913, respectively) for
the 5' untranslated region (5' UTR; corre-
sponding to nucleotides 595 to 699 of the
HPeV-3 A308/99 strain, accession no.
AB084913) (8,10). Asterisks denote identical
nucleotides in all strains, whereas shaded
nucleotides highlight differences between
HPeV-3 isolates.C-terminus of VP1 was absent in all Canadian isolates
(Appendix Figure). A phylogenetic tree confirming the
relationship between Canadian HPeV strains and other
HPeV-3 isolates is shown in Figure 2.
Conclusion
We report the first 3 cases of HPeV-3 infection outside
Japan and the first description of neonatal sepsis caused by
this virus. The initial article on HPeV-3 infection by Ito et
al. mentioned a case of transient paralysis with fever and
diarrhea in a 1-year-old infant, as well as 3 other cases of
gastroenteritis, exanthema, and respiratory illness,
although no other clinical information was provided (8). In
our study, viral infections occurred in the first month of
life, and all patients had relatively similar clinical signs,
including high fever, tachypnea, and erythematous rash.
Acute otitis media and conjunctivitis were also noted in 1
patient each. All infants had a complete microbiologic
work-up for possible bacteremia, including blood, urine
and cerebrospinal fluid cultures, and all patients received
at least 4 days of intravenous antimicrobial drugs for sus-
pected bacterial sepsis. Neonatal infections caused by
other HPeVs and many enteroviruses have been reported,
including outbreaks of respiratory diseases on neonatal
wards (11). Neonatal enteroviral infections can be severe,
depending on the timing of maternal infection relative to
time of delivery, and can progress to systemic disease,
which may include hepatic necrosis, myocarditis, and
necrotizing enterocolitis with or without neurologic
involvement (12). Similar to some of our cases, a preced-
ing maternal infection has been reported for 59% to 68%
of neonates with enteroviral infections (12).
Most symptomatic HPeV-1 infections have been report-
ed in young children, and most have been in children <1
year of age (3,5). For both HPeV-1 and the newly
described HPeV-3, the proportion of seropositive children
increases rapidly, reaching almost 100% by 5–6 years of
age in Japan (8,13). HPeV-3 does not seem to be a recent-
ly emerging pathogen, as 87% of Japanese adults >40
years of age have preexisting antibodies (8). The reasons
for the late description of this virus are unclear; as postu-
lated for the newly described human metapneumovirus
(14), a slow and restricted initial growth on a few cell lines
(e.g., tertiary monkey kidney cells) might be one possibil-
ity, although additional epidemiologic and virologic stud-
ies are needed. In addition, as previously reported (8),
HPeV-3 strains could not be neutralized with any antisera
against human picornaviruses, including those directed
against HPeV-1 and HPeV-2. The absence of the RGD
motif near the C-terminus of the VP1 protein may be one
of the epitopes involved in this event, since an antiserum
specific for this region exhibited neutralizing activity
against HPeV-1 (15). Also, the absence of the RGD motif
in HPeV-3 is probably related to receptor usage since this
region has been shown to interact with integrins (16,17).
One of the HPeV-1 antigenic sites described by Joki-
Korpela et al. (15), located near the N-terminal region of
the VP0 protein (amino acid 79–90), was also conserved in
our HPeV-3 strains as well as in reported HPeV-2 isolates
(except for 1 residue), which suggests that it might repre-
sent a group antigen (Appendix Figure). All 3 Canadian
strains isolated in the fall of 2001 were clearly related to
the prototype HPeV-3 strain from Japan recovered in 1999
and reported in 2004 (97.0%–97.1% amino acid identity
for the VP0-VP3-VP1 region), although point mutations
could discriminate all our strains (Figure 1 and Appendix
Figure).
In summary, we provide additional confirmation for a
third serotype of HPeV that could not be neutralized with
antisera against other known members of the Parechovirus
genus. Our case reports expand the clinical spectrum of
previously-reported HPeV-3 infections and highlight the
need for additional research work to characterize clinical
and epidemiologic features of this newly described
pathogen. Of particular interest are the proportion of
asymptomatic viral infections in childhood and the occur-
rence of reinfections in the adult population.
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Figure 2. Phylogenetic tree showing the relationship between
human parechovirus (HPeV)-3 Canadian isolates no. 81235,
81554, and 82853 and other HPeV-3 (A628-99, GenBank acces-
sion no. AB112484; A354-99, no. AB112483; A317-99, no.
AB112482; A308-99, no. AB084913), HPeV-2 (Williamson, no.
AJ005695; Connecticut, no. AF055846) and HPeV-1 (Harris, no.
S45208; A10987-00, no. AB112487; A942-99, no. AB112486;
A1086-99, no. AB112485) strains based on amino acid differences
in capsid proteins (VP0-VP3-VP1 region). The tree was construct-
ed by using the neighbor-joining method. Numbers represent the
frequency of occurrence of nodes in 500 bootstrap replicas.Dr. Boivin is a medical virologist and an infectious disease
specialist at the Centre Hospitalier Universitaire de Québec
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tion of emerging respiratory viral pathogens and the mechanisms
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